What Has Been the Growth Trajectory of the Small Molecule Drug Discovery Market?
The small molecule drug discovery market has seen considerable growth due to a variety of factors.
• In recent years, the market size for small molecule drug discovery has seen a robust growth. The market, estimated to be worth $62.44 billion in 2024, is projected to increase to $68.57 billion in 2025, representing a compound annual growth rate (CAGR) of 9.8%. The expansion in the historical period is linked to initiatives for drug repurposing, the automation of drug discovery, boosts in r&d investment, regulatory endorsement for drug development, and the advancements in high-throughput screening.
How Does the Forecast Look for the Small Molecule Drug Discovery Market By 2029?
The Small Molecule Drug Discovery market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, the market size for small molecule drug discovery is predicted to experience a swift expansion. The growth will reach a staggering $106.91 billion by 2029, with a compound annual growth rate (CAGR) of 11.7%.
Various factors contributing to this growth during the projected period include the appearance of innovative therapeutic targets, patient-centered drug discovery, the advent of drug-device combination products, the use of actual world evidence, integration of pharmacogenomics, and overall global health issues. Key trends during this period involve fragment-based drug discovery, the implementation of artificial intelligence in drug discovery, RNA-targeted treatments, collaborations and alliances, innovations in drug delivery, and the use of organoids and 3D cell culture models.
What Are The Leading Drivers Of Growth In The Small Molecule Drug Discovery Market?
The escalating prevalence of chronic illnesses is anticipated to fuel expansion in the small molecule drug discovery market. Chronic illnesses are defined as conditions that endure for over a year, interfere with daily tasks, necessitate ongoing medical attention, or both. Chronic conditions like HIV, cancer, infections, heart disease, and renal disease can be managed using small-molecule drugs, and these drugs tend to be financially accessible for patients with long-term illnesses. As a result, the escalating prevalence of chronic illness is anticipated to fuel the small molecule drug discovery market's growth. For example, a study by the National Institutes of Health (NIH), a biomedical research organization, projected that the number of individuals aged 50 and above in the United States with at least one chronic illness would increase by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Similarly, the population with multimorbidity is projected to surge by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Consequently, the escalating prevalence of chronic illnesses is driving the expansion of the small molecule drug discovery market.
How Are The Segments Defined Within The Global Small Molecule Drug Discovery Market?
The small molecule drug discovery market covered in this report is segmented –
1) By Drug Type: Small Molecule Drugs, Biologic Drugs
2) By Technology: High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, Others
3) By Therapeutic Area: Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal, Others
4) By Process Or Phase: Target ID Or Validation, Hit Generation And Selection, Lead Identification, Lead Optimization
5) By End-User: Pharmaceutical Companies, Contract Research Organizations, Others
Subsegments:
1) By Small Molecule Drugs: Generic Small Molecule Drugs, Novel Small Molecule Drugs
2) By Biologic Drugs: Monoclonal Antibodies, Vaccines, Recombinant Proteins, Cell And Gene Therapies
Pre-Book The Small Molecule Drug Discovery Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Small Molecule Drug Discovery Market?
Technological advancements are becoming a prominent trend within the small molecule drug discovery industry. Numerous prominent firms within this market are prioritizing the development of new products. For instance, Dotmatics, an American company specializing in digital science platforms, introduced its Small Molecule Drug Discovery Solution in January 2023. This unique solution is designed with a unified scientific R&D platform, complete with pre-planned workflows and increased data management abilities. It not only minimizes operational weaknesses, but also accelerates the process of converting data insights into decisions.
Who Are the Key Players In The Small Molecule Drug Discovery Market?
Major companies operating in the small molecule drug discovery market include:
• Pfizer Inc.
• GlaxoSmithKline plc
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Gilead Sciences Inc.
• Merck KGaA
• Novartis AG
• 4SC AG
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Labcorp Drug Development
• ICON Public Limited Company
• Charles River Laboratories
• Aluda Pharmaceuticals
• Clinuvel Pharmaceuticals
• Corcept Therapeutics
• Edison Oncology
• Escend Pharmaceuticals
• Terray Therapeutics
• Apollomics
• Astex Pharmaceuticals
• Pardes Biosciences
• Xynomic Pharmaceuticals
• Zevra Therapeutics
• UNION therapeutics
• Pharmacosmos
• Allarity Therapeutics
• Xellia Pharmaceuticals
• Cyteir Therapeutics
• BigHat Biosciences
What Is The Most Dominant Region In The Small Molecule Drug Discovery Market?
North America was the largest region in the small molecule drug discovery market in 2024. Europe is expected to be the fastest-growing region in the small molecule drug discovery market report during the forecast period. The regions covered in the small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
